Description
[ CAS NO. ] 920014-72-8
[ Molecular Formula ] C49H68N18O9S2
[ Molecular Weight ] 1117.32
[ Appearance ] White Powder
[ Purity ] 99%
[ Function ]
1. For the treatment of LEPR deficiency obesity;
2. May help restore function of the MC4R pathway in regulating body weight and controlling appetite;
About Setmelanotide
Setmelanotide is a first-in-class, oligopeptide MC4R agonist that restores function of the impaired MC4R pathway, which independently regulates energy expenditure and appetite.
Setmelanotide is an oligopeptide melanocortin-4 receptor (MC4R) agonist, which is part of a key biological pathway that independently regulates energy expenditure and appetite. Gene variants may impair the function of the MC4R pathway, which can lead to extreme hunger (hyperappetite) and early-onset severe obesity. Setmelanotide, as a targeted therapy, restores the function of the damaged MC4R pathway, re-establishes energy expenditure and appetite control, reduces hunger, and reduces body weight in patients with rare obesity genetic diseases.
Setmelanotide binds to and activates MC4 receptors in the paraventricular nucleus (PVN) and lateral hypothalamic area (LHA), an effect thought to underlie appetite suppression. Setmelanotide increases resting energy expenditure in obese animals and humans.
Currently, setmelanotide is being developed as a targeted therapy to restore the function of the damaged MC4R pathway, re-establish energy expenditure and appetite control, reduce hunger and reduce body weight in patients with rare genetic diseases of obesity. Currently, there are no drug therapies to treat these rare genetic diseases of obesity.
